RESUMO
Pure autonomic failure (PAF) is a neurodegenerative disease affecting the sympathetic component of the autonomic nervous system and presenting as orthostatic hypotension (OH). It is a rare, sporadic disease of adults. Although OH is the primary symptom, the autonomic dysfunction may be more generalised, leading to genitourinary and intestinal dysfunction and sweating disorders. Autonomic symptoms in PAF may be similar to those observed in other autonomic neuropathies that need to be ruled out. PAF belongs to the group of α synucleinopathies and is characterised by predominant peripheral deposition of α-synuclein in autonomic ganglia and nerves. However, in a significant number of cases, PAF may convert into another synucleinopathy with central nervous system involvement with varying prognosis: Parkinson's disease (PD), multiple system atrophy (MSA), or dementia with Lewy bodies (DLB). The clinical features, the main differential diagnoses, the risk factors for "phenoconversion" to another synucleinopathy as well as an overview of treatment will be discussed.
Assuntos
Doenças do Sistema Nervoso Autônomo , Doença por Corpos de Lewy , Atrofia de Múltiplos Sistemas , Doença de Parkinson , Insuficiência Autonômica Pura , Sinucleinopatias , Adulto , Humanos , Insuficiência Autonômica Pura/complicações , Insuficiência Autonômica Pura/diagnóstico , Insuficiência Autonômica Pura/terapia , Doença de Parkinson/complicações , Doença de Parkinson/diagnóstico , Doença de Parkinson/epidemiologia , Atrofia de Múltiplos Sistemas/complicações , Atrofia de Múltiplos Sistemas/diagnóstico , Atrofia de Múltiplos Sistemas/terapia , Doença por Corpos de Lewy/diagnóstico , Doenças do Sistema Nervoso Autônomo/diagnóstico , Doenças do Sistema Nervoso Autônomo/etiologiaRESUMO
Autonomic failure is frequently encountered in synucleinopathies such as multiple system atrophy (MSA), Parkinson's disease (PD), Lewy body disease, and pure autonomic failure (PAF). Cardiovascular autonomic failure affects quality of life and can be life threatening due to the risk of falls and the increased incidence of myocardial infarction, stroke, and heart failure. In PD and PAF, pathogenic involvement is mainly post-ganglionic, while in MSA, the involvement is mainly pre-ganglionic. Cardiovascular tests exploring the autonomic nervous system (ANS) are based on the analysis of continuous, non-invasive recordings of heart rate and digital blood pressure (BP). They assess facets of sympathetic and parasympathetic activities and provide indications on the integrity of the baroreflex arc. The tilt test is widely used in clinical practice. It can be combined with catecholamine level measurement and analysis of baroreflex activity and cardiac variability for a detailed analysis of cardiovascular damage. MIBG myocardial scintigraphy is the most sensitive test for early detection of autonomic dysfunction. It provides a useful measure of post-ganglionic sympathetic fiber integrity and function and is therefore an effective tool for distinguishing PD from other parkinsonian syndromes such as MSA. Autonomic cardiovascular investigations differentiate between certain parkinsonian syndromes that would otherwise be difficult to segregate, particularly in the early stages of the disease. Exploring autonomic failure by gathering information about residual sympathetic tone, low plasma norepinephrine levels, and supine hypertension can guide therapeutic management of orthostatic hypotension (OH).
Assuntos
Doenças do Sistema Nervoso Autônomo , Atrofia de Múltiplos Sistemas , Doença de Parkinson , Insuficiência Autonômica Pura , Sinucleinopatias , Humanos , Insuficiência Autonômica Pura/complicações , Insuficiência Autonômica Pura/diagnóstico , Insuficiência Autonômica Pura/terapia , Sinucleinopatias/complicações , Qualidade de Vida , Doenças do Sistema Nervoso Autônomo/diagnóstico , Doenças do Sistema Nervoso Autônomo/etiologia , Doenças do Sistema Nervoso Autônomo/terapia , Atrofia de Múltiplos Sistemas/complicações , Atrofia de Múltiplos Sistemas/diagnóstico , Atrofia de Múltiplos Sistemas/terapia , Doença de Parkinson/complicações , Doença de Parkinson/diagnóstico , Doença de Parkinson/terapiaRESUMO
PURPOSE: Pure autonomic failure (PAF) is a rare disease characterized by neurogenic orthostatic hypotension (nOH), no known secondary cause, and lack of a neurodegenerative movement or cognitive disorder. Clinically diagnosed PAF can evolve ("phenoconvert") to a central Lewy body disease [LBD, e.g., Parkinson's disease (PD) or dementia with Lewy bodies (DLB)] or to the non-LBD synucleinopathy multiple system atrophy (MSA). Since cardiac 18F-dopamine-derived radioactivity usually is low in LBDs and usually is normal in MSA, we hypothesized that patients with PAF with low cardiac 18F-dopamine-derived radioactivity would be more likely to phenoconvert to a central LBD than to MSA. METHODS: We reviewed data from all the patients seen at the National Institutes of Health Clinical Center from 1994 to 2023 with a clinical diagnosis of PAF and data about 18F-dopamine positron emission tomography (PET). RESULTS: Nineteen patients (15 with low 18F-dopamine-derived radioactivity, 4 with normal radioactivity) met the above criteria and had follow-up data. Nine (47%) phenoconverted to a central synucleinopathy over a mean of 6.6 years (range 1.5-18.8 years). All 6 patients with low cardiac 18F-dopamine-derived radioactivity who phenoconverted during follow-up developed a central LBD, whereas none of 4 patients with consistently normal 18F-dopamine PET phenoconverted to a central LBD (p = 0.0048), 3 evolving to probable MSA and 1 upon autopsy having neither a LBD nor MSA. CONCLUSION: Cardiac 18F-dopamine PET can predict the type of phenoconversion of PAF. This capability could refine eligibility criteria for entry into disease-modification trials aimed at preventing evolution of PAF to symptomatic central LBDs.
Assuntos
Doença por Corpos de Lewy , Atrofia de Múltiplos Sistemas , Insuficiência Autonômica Pura , Sinucleinopatias , Humanos , Insuficiência Autonômica Pura/diagnóstico por imagem , Insuficiência Autonômica Pura/complicações , Dopamina , Sinucleinopatias/complicações , Atrofia de Múltiplos Sistemas/complicações , Tomografia por Emissão de Pósitrons/métodos , Doença por Corpos de Lewy/diagnóstico por imagem , Doença por Corpos de Lewy/complicaçõesRESUMO
Pure autonomic failure (PAF) is a rare disease in which chronic neurogenic orthostatic hypotension (nOH) dominates the clinical picture. Longitudinal studies have reported that PAF can phenoconvert to a central synucleinopathy with motor or cognitive involvement-i.e., to Parkinson disease (PD), dementia with Lewy bodies (DLB), or multiple system atrophy (MSA). These studies have classified patients clinically as having PAF based on nOH without an identified secondary cause or clinical evidence of motor or cognitive impairment due to central neurodegeneration. This approach lumps together two nOH syndromes that are pathologically and neurochemically distinct. One is characterized by intraneuronal cytoplasmic alpha-synuclein aggregates (i.e., Lewy bodies) and degeneration of postganglionic sympathetic neurons, as in PD and DLB; the other is not, as in MSA. Clinical and postmortem data show that the form of PAF that involves sympathetic intraneuronal synucleinopathy and noradrenergic deficiency can phenoconvert to PD or DLB-but not to MSA. Conversely, PAF without these features leaves open the possibility of premotor MSA.
Assuntos
Doença por Corpos de Lewy , Atrofia de Múltiplos Sistemas , Doença de Parkinson , Insuficiência Autonômica Pura , Sinucleinopatias , Humanos , Doença de Parkinson/complicações , Insuficiência Autonômica Pura/complicaçõesRESUMO
Rapid eye movement sleep behavior disorder is characterized by dream enactment and complex motor behaviors during rapid eye movement sleep and rapid eye movement sleep atonia loss (rapid eye movement sleep without atonia) during polysomnography. Rapid eye movement sleep behavior disorder may be idiopathic or symptomatic and in both settings is highly associated with synucleinopathy neurodegeneration, especially Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, and pure autonomic failure. Rapid eye movement sleep behavior disorder frequently manifests years to decades prior to overt motor, cognitive, or autonomic impairments as the presenting manifestation of synucleinopathy, along with other subtler prodromal "soft" signs of hyposmia, constipation, and orthostatic hypotension. Between 35% and 91.9% of patients initially diagnosed with idiopathic rapid eye movement sleep behavior disorder at a sleep center later develop a defined neurodegenerative disease. Less is known about the long-term prognosis of community-dwelling younger patients, especially women, and rapid eye movement sleep behavior disorder associated with antidepressant medications. Patients with rapid eye movement sleep behavior disorder are frequently prone to sleep-related injuries and should be treated to prevent injury with either melatonin 3-12 mg or clonazepam 0.5-2.0 mg to limit injury potential. Further evidence-based studies about rapid eye movement sleep behavior disorder are greatly needed, both to enable accurate prognostic prediction of end synucleinopathy phenotypes for individual patients and to support the application of symptomatic and neuroprotective therapies. Rapid eye movement sleep behavior disorder as a prodromal synucleinopathy represents a defined time point at which neuroprotective therapies could potentially be applied for the prevention of Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, and pure autonomic failure. © 2017 International Parkinson and Movement Disorder Society.
Assuntos
Doença de Parkinson/fisiopatologia , Sintomas Prodrômicos , Transtorno do Comportamento do Sono REM/fisiopatologia , Depressores do Sistema Nervoso Central/uso terapêutico , Clonazepam/uso terapêutico , Moduladores GABAérgicos/uso terapêutico , Humanos , Doença por Corpos de Lewy/complicações , Doença por Corpos de Lewy/fisiopatologia , Melatonina/uso terapêutico , Atrofia de Múltiplos Sistemas/complicações , Atrofia de Múltiplos Sistemas/fisiopatologia , Doença de Parkinson/complicações , Polissonografia , Insuficiência Autonômica Pura/complicações , Insuficiência Autonômica Pura/fisiopatologia , Transtorno do Comportamento do Sono REM/tratamento farmacológico , Transtorno do Comportamento do Sono REM/etiologiaRESUMO
We describe the case of a man whose initial clinical presentation included sensorineural hearing loss and orthostatic hypotension. The patient was diagnosed with superficial siderosis associated with peripheral autonomic failure and tetraventricular hydrocephalus.
Assuntos
Quarto Ventrículo/diagnóstico por imagem , Hidrocefalia/diagnóstico por imagem , Insuficiência Autonômica Pura/diagnóstico por imagem , Siderose/diagnóstico por imagem , Idoso , Quarto Ventrículo/cirurgia , Humanos , Hidrocefalia/complicações , Hidrocefalia/cirurgia , Masculino , Insuficiência Autonômica Pura/complicações , Insuficiência Autonômica Pura/cirurgia , Siderose/complicações , Siderose/cirurgiaRESUMO
Patients with autonomic failure are characterized by orthostatic hypotension, supine hypertension, high blood pressure variability, blunted heart rate variability, and often have a "non-dipping" or "reverse dipping" pattern on 24-h ambulatory blood pressure monitoring. These alterations may lead to cardiovascular and cerebrovascular changes, similar to the target organ damage found in hypertension. Often patients with autonomic failure are on treatment with anti-hypotensive drugs, which may worsen supine hypertension. The aim of this review is to summarize the evidence for cardiac, vascular, renal, and cerebrovascular damage in patients with autonomic failure.
Assuntos
Doenças Cardiovasculares/etiologia , Insuficiência Autonômica Pura/complicações , Fármacos do Sistema Nervoso Autônomo/efeitos adversos , Fármacos do Sistema Nervoso Autônomo/uso terapêutico , Pressão Sanguínea/fisiologia , Doenças Cardiovasculares/patologia , Humanos , Insuficiência Autonômica Pura/patologiaRESUMO
Patients with autonomic failure experience orthostatic hypotension (OH) often leading to syncope. Arrhythmias may cause severe syncope, characterized by an increased risk of mortality. We report two cases of patients with primary autonomic neuropathy suffering from both severe OH and arrhythmic syncope.
Assuntos
Arritmias Cardíacas/etiologia , Hipotensão Ortostática/complicações , Síncope/etiologia , Anti-Inflamatórios/uso terapêutico , Doenças do Sistema Nervoso Autônomo/complicações , Eletrocardiografia Ambulatorial , Feminino , Fludrocortisona/uso terapêutico , Humanos , Masculino , Pessoa de Meia-Idade , Marca-Passo Artificial , Insuficiência Autonômica Pura/complicações , Insuficiência Autonômica Pura/tratamento farmacológico , Insuficiência Autonômica Pura/fisiopatologia , ReflexoRESUMO
Cardiovascular autonomic failure is the second most common dysautonomic feature of α-synucleinopathies and has significant impact on daily activities and quality of life. Here we provide a systematic review of cardiovascular autonomic failure in α-synucleinopathies, emphasizing its impact on cognitive functions and disease outcomes. Articles spanning the period between January 1985 and April 2012 were identified from the PubMed database using a keyword-based search. Epidemiological studies highlight the negative prognostic effect of cardiovascular autonomic failure on cardiovascular and cerebrovascular outcomes and overall mortality in all α-synucleinopathies. Altered cerebral perfusion, vascular pressure stress, and related disruption of the blood-brain barrier may also contribute to the white matter hyperintensities and cognitive dysfunction frequently found in patients affected by neurocardiovascular instability. These findings support the hypothesis that cardiovascular autonomic failure may play a negative prognostic role in α-synucleinopathies and suggest that precocious screening and therapeutic management of cardiovascular autonomic failure may positively impact disease course.
Assuntos
Sistema Cardiovascular/fisiopatologia , Doenças Neurodegenerativas/diagnóstico , Doenças Neurodegenerativas/fisiopatologia , Disautonomias Primárias/diagnóstico , Disautonomias Primárias/fisiopatologia , alfa-Sinucleína/metabolismo , Encéfalo/irrigação sanguínea , Encéfalo/fisiopatologia , Transtornos Cognitivos/complicações , Transtornos Cognitivos/fisiopatologia , Progressão da Doença , Fadiga/complicações , Fadiga/fisiopatologia , Humanos , Hipotensão Ortostática/complicações , Hipotensão Ortostática/fisiopatologia , Doença por Corpos de Lewy , Atrofia de Múltiplos Sistemas , Doenças Neurodegenerativas/complicações , Doença de Parkinson , Disautonomias Primárias/complicações , Prognóstico , Insuficiência Autonômica Pura/complicações , Insuficiência Autonômica Pura/diagnóstico , Insuficiência Autonômica Pura/fisiopatologia , alfa-Sinucleína/genéticaAssuntos
Hipertensão/fisiopatologia , Doença de Parkinson/fisiopatologia , Insuficiência Autonômica Pura/fisiopatologia , Decúbito Dorsal/fisiologia , Idoso , Humanos , Hipertensão/complicações , Hipertensão/diagnóstico , Masculino , Doença de Parkinson/diagnóstico , Insuficiência Autonômica Pura/complicações , Insuficiência Autonômica Pura/diagnóstico , Resultado do TratamentoRESUMO
Aim: This study explores the burden of caring for an individual with neurogenic orthostatic hypotension (nOH) and an underlying neurodegenerative disease (Parkinson's disease, multiple system atrophy, pure autonomic failure or dementia with Lewy bodies). Materials & methods: A survey including several validated instruments was conducted with informal caregivers of individuals with Parkinson's disease, multiple system atrophy, pure autonomic failure or dementia with Lewy bodies. Results: Caregivers of patients with nOH (n = 60) reported greater burden across all outcomes compared with those without nOH (n = 60). Receiving pharmacological treatment for nOH was the variable most consistently associated with significantly better caregiver health-related quality-of-life (p < 0.05). Conclusion: This study demonstrates the burden of nOH on informal caregivers and highlights the potential benefit of pharmacological treatment not only for patients but also indirectly, their caregivers.
Neurogenic orthostatic hypotension (nOH) causes blood pressure to fall when you stand up, meaning you can feel dizzy or lightheaded. This study looked at how providing day to day caregiving support to someone who has nOH as well as another neurological condition impacts the caregiver's health and wellbeing. These neurological conditions included Parkinson's disease, multiple system atrophy, pure autonomic failure or dementia with Lewy bodies. A survey was conducted with informal caregivers (e.g., family members) of people with a neurological condition, with or without nOH. Caregivers completed questions about their own health-related quality-of-life, anxiety, depression and experience of caregiving. Caregivers of patients with nOH reported higher amounts of burden compared with those without nOH. Patients taking a treatment for nOH was most often associated with better caregiver health-related quality-of-life. This study shows the burden nOH can have on informal caregivers and highlights that treatment potentially benefits both patients and, indirectly, caregivers.
Assuntos
Hipotensão Ortostática , Doença por Corpos de Lewy , Atrofia de Múltiplos Sistemas , Doença de Parkinson , Insuficiência Autonômica Pura , Humanos , Hipotensão Ortostática/complicações , Hipotensão Ortostática/tratamento farmacológico , Cuidadores , Doença de Parkinson/complicações , Insuficiência Autonômica Pura/complicações , Doença por Corpos de Lewy/tratamento farmacológico , Qualidade de VidaRESUMO
Over the past century, generations of neuroscientists, pathologists, and clinicians have elucidated the underlying causes of autonomic failure found in neurodegenerative, inherited, and antibody-mediated autoimmune disorders, each with pathognomonic clinicopathologic features. Autonomic failure affects central autonomic nervous system components in the α-synucleinopathy, multiple system atrophy, characterized clinically by levodopa-unresponsive parkinsonism or cerebellar ataxia, and pathologically by argyrophilic glial cytoplasmic inclusions (GCIs). Two other central neurodegenerative disorders, pure autonomic failure characterized clinically by deficits in norepinephrine synthesis and release from peripheral sympathetic nerve terminals; and Parkinson's disease, with early and widespread autonomic deficits independent of the loss of striatal dopamine terminals, both express Lewy pathology. The rare congenital disorder, hereditary sensory, and autonomic neuropathy type III (or Riley-Day, familial dysautonomia) causes life-threatening autonomic failure due to a genetic mutation that results in loss of functioning baroreceptors, effectively separating afferent mechanosensing neurons from the brain. Autoimmune autonomic ganglionopathy caused by autoantibodies targeting ganglionic α3-acetylcholine receptors instead presents with subacute isolated autonomic failure affecting sympathetic, parasympathetic, and enteric nervous system function in various combinations. This chapter is an overview of these major autonomic disorders with an emphasis on their historical background, neuropathological features, etiopathogenesis, diagnosis, and treatment.
Assuntos
Doenças Autoimunes , Doenças do Sistema Nervoso Autônomo , Atrofia de Múltiplos Sistemas , Doença de Parkinson , Doenças do Sistema Nervoso Periférico , Insuficiência Autonômica Pura , Humanos , Insuficiência Autonômica Pura/complicações , Doenças do Sistema Nervoso Autônomo/genética , Doenças do Sistema Nervoso Autônomo/diagnóstico , Sistema Nervoso Autônomo , Atrofia de Múltiplos Sistemas/genética , Atrofia de Múltiplos Sistemas/complicações , Doenças Autoimunes/complicaçõesAssuntos
Antiparkinsonianos/uso terapêutico , Droxidopa/uso terapêutico , Hipotensão Ortostática/complicações , Hipotensão Ortostática/tratamento farmacológico , Doença de Parkinson/complicações , Doença de Parkinson/tratamento farmacológico , Avaliação da Deficiência , Interações Medicamentosas , Humanos , Masculino , Pessoa de Meia-Idade , Insuficiência Autonômica Pura/complicaçõesRESUMO
A cardinal manifestation of chronic autonomic failure is neurogenic orthostatic hypotension (OH), which often is associated with supine hypertension, posing a therapeutic dilemma. We report here success in a first step toward development of a "prosthetic baroreceptor system" to maintain blood pressure during orthostasis without worsening supine hypertension. In all of four patients with neurogenic OH, titrated i.v. NE infusion kept directly recorded intra-arterial pressure at or above baseline during progressive head-up tilt. We conclude that titrated i.v. NE infusion temporarily eliminates OH.
Assuntos
Hipotensão Ortostática/tratamento farmacológico , Norepinefrina/uso terapêutico , Insuficiência Autonômica Pura/complicações , Vasoconstritores/uso terapêutico , Pressão Sanguínea/efeitos dos fármacos , Humanos , Hipotensão Ortostática/etiologia , Infusões Intra-Arteriais , Doença de Parkinson/complicações , Doença de Parkinson/tratamento farmacológico , Insuficiência Autonômica Pura/tratamento farmacológico , Teste da Mesa Inclinada , Resultado do TratamentoRESUMO
Pure autonomic failure is a neurodegenerative disorder affecting the autonomic nervous system which clinically presents with orthostatic hypotension. It is a diagnosis of exclusion after detailed clinical examinations and relevant investigations. Here, we discuss a case of 68 years old male who had complaints of multiple episodes of loss of consciousness on standing from a sitting position for the last 3 years. The diagnosis was considered by clinical examinations revealing autonomic dysfunctions with normal appropriate investigations. The patient was treated successfully with midodrine, fludrocortisone, and other non-pharmacological interventions. We focused on doing various autonomic dysfunction tests in the evaluation of a patient with recurrent orthostatic hypotension. We suspect that pure autonomic failure might not have been considered in the differential diagnosis of recurrent orthostatic hypotension and suggest that it is to be kept as a differential in such a scenario. Midodrine has an effective role in syncope due to sympathetic vasoconstrictor failure.
Assuntos
Doenças do Sistema Nervoso Autônomo , Hipotensão Ortostática , Insuficiência Autonômica Pura , Idoso , Sistema Nervoso Autônomo , Doenças do Sistema Nervoso Autônomo/diagnóstico , Diagnóstico Diferencial , Humanos , Hipotensão Ortostática/diagnóstico , Hipotensão Ortostática/terapia , Masculino , Insuficiência Autonômica Pura/complicações , Insuficiência Autonômica Pura/diagnóstico , Insuficiência Autonômica Pura/terapiaRESUMO
Background Supine hypertension affects a majority of patients with autonomic failure; it is associated with end-organ damage and can worsen daytime orthostatic hypotension by inducing pressure diuresis and volume loss during the night. Because sympathetic activation prevents blood pressure (BP) from falling in healthy subjects exposed to heat, we hypothesized that passive heat had a BP-lowering effect in patients with autonomic failure and could be used to treat their supine hypertension. Methods and Results In Protocol 1 (n=22), the acute effects of local heat (40-42°C applied with a heating pad placed over the abdomen for 2 hours) versus sham control were assessed in a randomized crossover fashion. Heat acutely decreased systolic BP by -19±4 mm Hg (versus 3±4 with sham, P<0.001) owing to decreases in stroke volume (-18±5% versus -4±4%, P=0.013 ) and cardiac output (-15±5% versus -2±4%, P=0.013). In Protocol 2 (proof-of-concept overnight study; n=12), we compared the effects of local heat (38°C applied with a water-perfused heating pad placed under the torso from 10 pm to 6 am) versus placebo pill. Heat decreased nighttime systolic BP (maximal change -28±6 versus -2±6 mm Hg, P<0.001). BP returned to baseline by 8 am. The nocturnal systolic BP decrease correlated with a decrease in urinary volume (r=0.57, P=0.072) and an improvement in the morning upright systolic BP (r=-0.76, P=0.007). Conclusions Local heat therapy effectively lowered overnight BP in patients with autonomic failure and supine hypertension and offers a novel approach to treat this condition. Future studies are needed to assess the long-term safety and efficacy in improving nighttime fluid loss and daytime orthostatic hypotension. Registration URL: https://www.clinicaltrials.gov; Unique identifiers: NCT02417415 and NCT03042988.
Assuntos
Sistema Nervoso Autônomo/fisiopatologia , Pressão Sanguínea/fisiologia , Hipertensão/terapia , Hipertermia Induzida/métodos , Insuficiência Autonômica Pura/complicações , Idoso , Feminino , Temperatura Alta , Humanos , Hipertensão/complicações , Hipertensão/fisiopatologia , Masculino , Insuficiência Autonômica Pura/fisiopatologia , Resultado do TratamentoRESUMO
Leg crossing increases arterial pressure and combats symptomatic orthostatic hypotension in patients with sympathetic failure. This study compared the central and cerebrovascular effects of leg crossing in patients with sympathetic failure and healthy controls. We addressed the relationship between MCA Vmean (middle cerebral artery blood velocity; using transcranial Doppler ultrasound), frontal lobe oxygenation [O2Hb (oxyhaemoglobin)] and MAP (mean arterial pressure), CO (cardiac output) and TPR (total peripheral resistance) in six patients (aged 37-67 years; three women) and age- and gender-matched controls during leg crossing. In the patients, leg crossing increased MAP from 58 (42-79) to 72 (52-89) compared with 84 (70-95) to 90 (74-94) mmHg in the controls. MCA Vmean increased from 55 (38-77) to 63 (45-80) and from 56 (46-77) to 64 (46-80) cm/s respectively (P<0.05), with a larger rise in O2Hb [1.12 (0.52-3.27)] in the patients compared with the controls [0.83 (-0.11 to 2.04) micromol/l]. In the control subjects, CO increased 11% (P<0.05) with no change in TPR. By contrast, in the patients, CO increased 9% (P<0.05), but also TPR increased by 13% (P<0.05). In conclusion, leg crossing improves cerebral perfusion and oxygenation both in patients with sympathetic failure and in healthy subjects. However, in healthy subjects, cerebral perfusion and oxygenation were improved by a rise in CO without significant changes in TPR or MAP, whereas in patients with sympathetic failure, cerebral perfusion and oxygenation were improved through a rise in MAP due to increments in both CO and TPR.
Assuntos
Doenças do Sistema Nervoso Autônomo/fisiopatologia , Débito Cardíaco/fisiologia , Hipotensão Ortostática/fisiopatologia , Perna (Membro)/fisiopatologia , Adulto , Idoso , Doenças do Sistema Nervoso Autônomo/complicações , Velocidade do Fluxo Sanguíneo/fisiologia , Pressão Sanguínea/fisiologia , Circulação Cerebrovascular/fisiologia , Feminino , Humanos , Hipotensão Ortostática/etiologia , Perna (Membro)/irrigação sanguínea , Masculino , Pessoa de Meia-Idade , Atrofia de Múltiplos Sistemas/complicações , Atrofia de Múltiplos Sistemas/fisiopatologia , Consumo de Oxigênio/fisiologia , Postura/fisiologia , Insuficiência Autonômica Pura/complicações , Insuficiência Autonômica Pura/fisiopatologiaRESUMO
We present a case report of severe autonomic failure in a 43-year-old well-controlled HIV patient. Clinical and pharmacological autonomic function testing supported the diagnosis of peripheral autonomic failure. Simple physiological manoeuvres substantially improved symptoms.